An endogenous brake on the sympathetic nervous system: The emerging role of catestatin in hypertension

Journal of Cardiovascular Medicine

Volumn 12, Issue 9, 2011, Pages 609-612

  Schillaci, Giuseppe ^a   De Vuono, Stefano ^a   Pucci, Giacomo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

catestatin; chromogranin A; hypertension; left ventricular hypertrophy

Indexed keywords

CATESTATIN; CHROMOGRANIN A; NORADRENALIN;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; DISEASE SEVERITY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HISTAMINE RELEASE; HOMEOSTASIS; HOSPITALIZATION; HUMAN; HYPERTENSION; PROTEIN FUNCTION; REVIEW; SYMPATHETIC NERVE; SYMPATHETIC TONE;

CHROMOGRANIN A; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PEPTIDE FRAGMENTS;

EID: 80051712297     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328348d925     Document Type: Review

References (33)

1. Julius S, Pasqual AV, London R. Role of parasympathetic inhibition in the hypokinetic type of borderline hypertension. Circulation 1971; 44:413-418.
2. Goldstein DS, Kopin IJ. The autonomic nervous system and catecholamines in normal blood pressure control and in hypertension. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press Publishers; 1990. pp. 711- 747.
3. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension 1983; 5:86-99. (Pubitemid 13179794)
4. Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; 16:1979-1987. (Pubitemid 29002377)
5. Ferrier C, Esler MD, Eisenhofer G, et al. Increased norepinephrine spillover into cerebrovascular circulation in essential hypertension: evidence of high central nervous system norepinephrine turnover? Hypertension 1992; 19:62-69.
6. Anderson EA, Sinkey CA, Lawton WJ,Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension 1988; 14:1277-1283.
7. Ferrier C, Cox H, Esler M. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clin Sci (Lond) 1993; 84:225-230. (Pubitemid 23053230)
8. Morgan H, Baker KN. Cardiac hypertrophy, mechanical, neural, and endocrine dependence. Circulation 1991; 83:13-25.
9. Izzo JL Jr. Sympathoadrenal activity, catecholamines, and the pathogenesis of vasculopathic hypertensive target-organ damage. Am J Hypertens 1989; 2:305S-312S. (Pubitemid 20044846)
10. Zeng C, Zhang M, Asico LD, Eisner GM, Jose PA. The dopaminergic system in hypertension. Clin Sci (Lond) 2007; 112:583-597. (Pubitemid 46849549)
11. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134-1149. (Pubitemid 36337325)
12. Kim T, Tao-Cheng JH, Eiden LE, Loh YP, Chromogranin A. an 'on/off' switch controlling dense-core secretory granule biogenesis. Cell 2001; 106:499-509. (Pubitemid 32786993)
13. Huh YH, Jeon SH, Yoo SH. Chromogranin B-induced secretory granule biogenesis: comparison with the similar role of chromogranin A. J Biol Chem 2003; 278:40581-40589. (Pubitemid 37280870)
14. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007; 64:2863-2886. (Pubitemid 351152248)
15. Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002; 23:967-974. (Pubitemid 35203876)
16. Estensen ME, Hognestad A, Syversen U, et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 2006; 152:927e1-9276e.
17. Jansson AM, Rosjo H, Omland T, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009; 30:25-32.
18. Chen Y, Rao F, Rodriguez-Flores JL, et al. Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol 2008; 52:1468-1481.
19. Simon JP, Bader MF, Aunis D. Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc Natl Acad Sci U S A 1988; 85:1712-1716.
20. Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100:1623-1633. (Pubitemid 27425790)
21. Mahapatra NR, O'Connor DT, Vaingankar SM, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115:1942-1952. (Pubitemid 40979734)
22. Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 1998; 19:1241-1248. (Pubitemid 28475128)
23. Krü ger PG, Mahata SK, Helle KB. Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept 2003; 114:29-35.
24. Fung MM, Salem RM, Mehtani P, et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 2010; 32:278-287.
25. Rao F, Wen G, Gayen JR, et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007; 115:2271-2281. (Pubitemid 46685895)
26. Theurl M, Schgoer W, Albrecht K, et al. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res 2010; 107:1326-1335.
27. Meng L, Ye XJ, Ding WH, et al. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown) 2011.
28. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002; 20:1335-1345. (Pubitemid 34925678)
29. Mahata SK, Mahata M, Parmer RJ, O'Connor DT. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999; 274:2920-2928. (Pubitemid 29075379)
30. Vaingankar SM, Li Y, Biswas N, et al. Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens 2010; 28:817-825.
31. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565. (Pubitemid 36961170)
32. Strand AH, Gudmundsdottir H, Os I, et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens 2006; 24:905-913. (Pubitemid 43670462)
33. Biswas N, Curello E, O'Connor DT, Mahata SK. Chromogranin/ secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res 2010; 342:353-361.